Up­dat­ed: Eu­ro­pean Com­mis­sion au­tho­rizes No­vavax's up­dat­ed Covid vac­cine

Fol­low­ing the Eu­ro­pean Med­i­cines Agency’s hu­man med­i­cines com­mit­tee (CHMP) rec­om­men­da­tion, the Eu­ro­pean Com­mis­sion has au­tho­rized for use No­vavax’s adapt­ed Nu­vax­ovid boost­er vac­cine for pre­vent­ing the Omi­cron XBB.1.5 sub­vari­ant of the coro­n­avirus in adults and ado­les­cents 12 years of age and old­er.

The de­ci­sion was based on non-clin­i­cal da­ta show­ing that No­vavax’s up­dat­ed vac­cine in­duced func­tion­al im­mune re­spons­es against the XBB.1.5, XBB.1.16 and XBB.2.3 vari­ants.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.